Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Raised by Hantz Financial Services Inc.

Hantz Financial Services Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,753 shares of the medical research company’s stock after acquiring an additional 1,046 shares during the period. Thermo Fisher Scientific comprises about 0.8% of Hantz Financial Services Inc.’s investment portfolio, making the stock its 20th biggest holding. Hantz Financial Services Inc.’s holdings in Thermo Fisher Scientific were worth $47,477,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. LRI Investments LLC acquired a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $127,000. Sanibel Captiva Trust Company Inc. lifted its stake in Thermo Fisher Scientific by 16.7% in the 1st quarter. Sanibel Captiva Trust Company Inc. now owns 1,828 shares of the medical research company’s stock worth $1,062,000 after acquiring an additional 262 shares in the last quarter. Community Trust & Investment Co. increased its holdings in shares of Thermo Fisher Scientific by 0.3% in the 1st quarter. Community Trust & Investment Co. now owns 33,455 shares of the medical research company’s stock valued at $19,444,000 after purchasing an additional 104 shares during the period. PGGM Investments increased its stake in shares of Thermo Fisher Scientific by 0.8% in the first quarter. PGGM Investments now owns 198,517 shares of the medical research company’s stock worth $115,380,000 after acquiring an additional 1,585 shares during the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Thermo Fisher Scientific by 245.9% during the 1st quarter. Cetera Investment Advisers now owns 56,914 shares of the medical research company’s stock valued at $33,079,000 after buying an additional 40,460 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 9,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares in the company, valued at $8,076,178.88. This trade represents a 38.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,150 shares of company stock valued at $20,651,865. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Bank of America upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $8.68 on Thursday, hitting $521.66. 2,914,199 shares of the company were exchanged, compared to its average volume of 1,509,342. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average of $569.98 and a two-hundred day moving average of $578.78. Thermo Fisher Scientific Inc. has a 1-year low of $480.57 and a 1-year high of $627.88. The company has a market cap of $199.53 billion, a P/E ratio of 32.71, a P/E/G ratio of 3.40 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same period last year, the firm earned $5.69 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.